Drugs Made In America Acquisition Corp. 8-K

What Happened
On March 23, 2026, Drugs Made In America Acquisition Corp. announced it issued an interim convertible note for $100,000 to BV Advisory Partners, LLC as an initial loan toward a contemplated $500,000 financing under a Definitive Interim Investment and Sponsor Transition Agreement. The Interim Note matures six months from issuance, carries no interest, and may be converted (at the investor’s option) into shares of the combined entity upon consummation of an initial business combination at a conversion price equal to a 35% discount to the market price at conversion. The company said proceeds will be used for accounting, audit and other expenses related to a business combination; it has not yet entered into a business combination agreement.

Key Details

• Interim loan amount: $100,000 issued March 23, 2026.
• Contemplated total financing: $500,000 under the Investment Agreement.
• Terms: six-month maturity, no interest, investor conversion option at a 35% discount to market price upon a Business Combination.
• Use of proceeds: accounting, audit and other expenses related to a Business Combination.

Why It Matters
This filing creates a short-term financial obligation and provides immediate bridge funding for deal-related expenses. If converted after a business combination, the note could dilute existing shareholders because conversion is at a 35% discount to market price. The note’s six-month maturity and conversion option are material items investors should note when assessing near-term financing needs, potential dilution, and the company’s progress toward completing a business combination.